{
  "id": "5e7f64a5835f4e477700001e",
  "type": "yesno",
  "question": "Can CMB305 be used against sarcomas?",
  "ideal_answer": "Yes, the CMB205 vaccine is aimed at synovial sarcoma and myxoid/round cell liposarcoma patients.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29280411"
  ],
  "snippets": [
    {
      "text": "CMB305 induces NY-ESO-1 specific T cell responses in both SS and MRC patients and these patients had excellent overall survival (OS) outcomes in the initial phase I study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29280411",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Data suggesting this vaccine may improve OS for SS and MRCL patients is exciting but early, and on-going work is testing the impact of CMB305 on patient outcomes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29280411",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29280411",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}